STAINES-UPON-THAMES, United Kingdom, June 11, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at the Mandarin Oriental, 80 Columbus Circle, New York.

Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8 a.m. Eastern.

Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.

ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations Daniel J. Speciale, CPA Vice President, Investor Relations and IRO 314-654-3638 daniel.speciale@mnk.com

Media Daniel Yunger Kekst CNC 212-521-4879 mallinckrodt@kekstcnc.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt. 6/19

View original content to download multimedia: http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-bmo-capital-markets-2019-prescriptions-for-success-healthcare-conference-300864805.html

SOURCE Mallinckrodt Pharmaceuticals

Subscribe to Daily Headlines

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

For copyright information, check with the distributor of this item, PR Newswire.

Load comments